Of Mice and Men and Elephants: Does Size Determine Our Cancer Risk?
In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent story in the New York Times about the paradox of mammal size and cancer risk. Oncologists at the University of Utah's Huntsman Cancer Institute and evolutionary biologists at the University of Chicago have published a study that examines the uncanny ability of our largest mammals, elephants, to fight cancer. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 16, 2015 Category: Hematology Source Type: news
IMF's 9th Annual Comedy Gala Raises $600,000 for Myeloma Research
The IMF's 9th Annual Comedy Celebration was a great success again this year, raising $600,000 for the Peter Boyle Research Fund and the IMF's Black Swan Research Initiative. "Anyone who was lucky enough to be at the Wilshire Ebell Theatre on Saturday night will tell you Peter Boyle's memory —and legacy of laughter á is alive and well," writes LA Times reporter Adam Tschorn in his coverage of the evening. View a photo gallery of the event and read the full story, HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 15, 2015 Category: Hematology Source Type: news
In the News: Myeloma Debates, Drug Costs, Reading that Matters
IMF Chairman Dr. Brian Durie recaps the International Myeloma Workshop (IMW) meeting in Rome, where myeloma experts debated, among other questions, whether we are curing myeloma. He also comments on recent news articles investigating the rise of drug prices, the value of calcium supplements, and if tea is as good for you as coffee. And finally, he connects the dots between antimatter and PET scans. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 12, 2015 Category: Hematology Source Type: news
Register now for the Stamfort, CT Patient & Family Seminar - Oct. 16-17, Stamford Mariott Hotel & Spa
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 9, 2015 Category: Hematology Source Type: news
Click here to view the replay of Living Well with Myeloma: NLB Members Answers Key Patient and Caregiver Questions teleconference
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, Ohio
Teresa Miceli, RN, BSN, OCN
Mayo Clinic-Rochester
Rochester, Minnesota
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 8, 2015 Category: Hematology Source Type: news
ARROW clinical trial fact sheet
A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 7, 2015 Category: Hematology Source Type: news
Exciting Silent Auctions Items Continue to Stack Up for IMF's 9th Annual Comedy Celebration
Not only is this year's 9th Annual Comedy Celebration gala packed with talented comics Tig Notaro, Fred Willard, and Heather McDonald, but the number of silent auction items up for bidding continues to grow! Unique experiences like a visit to the “NBC Nightly News with Lester Holt” broadcast control booth; a visit to the set of “New Girl,” starring Zooey Deschanel; and an autographed guitar signed by Joe Walsh have all been added. Remember, proceeds from the event benefit the Peter Boyle Research Fund, as well as support the Black Swan Research Initiative®, the IMF's collaborative project aimed at developing t...
Source: International Myeloma Foundation - October 2, 2015 Category: Hematology Source Type: news
Black Swan Research Initiative Team Member Wins Prestigious Award
Dr. Bruno Paiva, a member of IMF's Black Swan Research Initiative team, won the Bart Barlogie Young Investigator Award on Saturday at the International Myeloma Workshop in Rome. Dr. Paiva's primary research area is the assessment of minimal residual disease (MRD), and in his blog this week, IMF Chairman Dr. Brian Durie writes, "This award acknowledges Bruno individually and the importance of the MRD approach to searching for a cure for myeloma." (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 1, 2015 Category: Hematology Source Type: news
Register for the Living Well with Myeloma: NLB Members Answers Key Patient and Caregiver Questions
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, Ohio
Teresa Miceli, RN, BSN, OCN
Mayo Clinic-Rochester
Rochester, Minnesota (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 29, 2015 Category: Hematology Source Type: news
New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the study, calls the phase I-II results “remarkably good.” According to Dr. Durie, the well-tolerated regime produces remissions lasting approximately one year, and overall survival of close to two years, in the very-poor-risk setting of double refractory disease in which patients are resistant to both lenalidomide (Revlimid®) and bortezomib (Velcade®). (Source: ...
Source: International Myeloma Foundation - September 25, 2015 Category: Hematology Source Type: news
Janssen's daratumumab accepted for accelerated CHMP assessment for treatment of European patients with heavily pre-treated multiple myeloma
Janssen-Cilag International NV announced on September 25, 2015 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted its request for an accelerated assessment of the daratumumab Marketing Authorisation Application (MAA). This acceptance follows the earlier regulatory submission of a MAA which seeks authorisation of daratumumab as a single agent for the treatment of patients with relapsed and refractory multiple myeloma and is currently pending validation by the EMA. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 25, 2015 Category: Hematology Source Type: news
Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop
Takeda Pharmaceutical Company Limited on September 22, 2015 announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 22, 2015 Category: Hematology Source Type: news
FDA Grants Priority Review for Amgen's sNDA for Expanded Labeling of Kyprolis & #174; in Relapsed Multiple Myeloma
The US Food and Drug Administration (FDA) has agreed for priority review of Amgen's supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 21, 2015 Category: Hematology Source Type: news
FDA Grants Priority Review for Amgen's sNDA for Expanded Labeling of Kyprolis® in Relapsed Multiple Myeloma
The US Food and Drug Administration (FDA) has agreed for priority review of Amgen's supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 21, 2015 Category: Hematology Source Type: news
Huge Interest in Toxic Chemicals Triggered by Last Week's Blog: Follow-up Notes
In a follow-up to last week's blog about Agent Orange, IMF Chairman Dr. Brian Durie writes that a new report suggesting a link between home pesticide use and the risk of childhood cancers - especially blood cancers such as leukemia and lymphoma - could have implications for adults. Also, news that New York Times food columnist Mark Bittman is putting down his pen to take action. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 19, 2015 Category: Hematology Source Type: news
